Prosecution Insights
Last updated: April 19, 2026
Application No. 17/768,053

AN ANTIBODY, A PHARMACEUTICAL COMPOSITION, AND A METHOD

Final Rejection §112
Filed
Apr 11, 2022
Examiner
HOWARD, ZACHARY C
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Chugai Seiyaku Kabushiki Kaisha
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
599 granted / 940 resolved
+3.7% vs TC avg
Strong +38% interview lift
Without
With
+38.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
46 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
4.3%
-35.7% vs TC avg
§103
17.6%
-22.4% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
37.2%
-2.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 940 resolved cases

Office Action

§112
DETAILED ACTION Status of Application, Amendments and/or Claims The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The amendment of 2/19/26 has been entered in full. Claims 1-2, 5-6, 13-14, and 21 are amended. Claims 1-21 are pending. Applicants' election without traverse of Group I, claims 1-14 and 19-21, was previously acknowledged. Claims 15-18 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-14 and 19-21 are under consideration. Information Disclosure Statement The Information Disclosure Statement of 2/19/26 has been considered. Withdrawn Objections and/or Rejections The following page numbers refer to the previous Office Action (8/28/25). The objection to the drawings at page 2 is withdrawn in view of the replacement sheets filed 2/19/26. The objections to the specification at page 3 are withdrawn in view of the amendments to the specification. The objections to claims 1-14 and 19-21 at pages 3-4 are withdrawn in view of the amendments to the claims. Maintained Objections and/or Rejections Claim Rejections - 35 USC § 112(a), written description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.-The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-4 and 19-21 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection was set forth previously at pages 4-8 of the 8/28/25 Office Action. Applicants’ arguments (2/19/26; page 14) as they pertain to the rejection have been fully considered but are not deemed to be persuasive for the following reasons. In the response, Applicants request that the rejection “be reconsidered and withdrawn”, because that “the claims are adequately described because a skilled artisan considering the specification would have reasonably concluded that the inventors had possession of the instantly claimed antibody” (page 14). Applicants’ arguments have been fully considered but are not found persuasive. Applicants’ argument, that the skilled artisan would have concluded that the inventors had possession of the claimed antibody, merely states the opposite conclusion of the rejection of record; i.e., that the skilled artisan would not held that Applicants have possession of the claimed invention. The rejection of record established a prima facie case reaching this conclusion, and supported by a reasoned explanation; see pages 4-8 of the Office action. Applicants’ arguments do not provide any specific reasons as to why the explanation that leads to this conclusion is wrong. As such, the rejection is maintained for the reasons of record. New Claim Objections Claim 6 is objected to because of the following informalities: In claim 6, lines 2-3, the recitation “…wherein the heavy chain variable region comprising HVR-H1…” should be “…wherein the heavy chain variable region comprises HVR-H1…” In claim 6, lines 6-7, the recitation “…wherein the light chain variable region comprising HVR-L1…” should be “…wherein the light chain variable region comprises HVR-L1…” Appropriate correction is required. Conclusion Claims 5 and 7-14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZACHARY C HOWARD whose telephone number is (571)272-2877. The examiner can normally be reached on Monday to Friday from 9 AM to 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford, can be reached at telephone number (571) 272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated-interview-request-air-form. /ZACHARY C HOWARD/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Apr 11, 2022
Application Filed
Aug 21, 2025
Non-Final Rejection — §112
Feb 19, 2026
Response Filed
Mar 27, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599654
IMMUNOGENIC PEPTIDE FRAGMENTS OF METALLOPROTEASE ADAMTS-7 AND USES THEREOF IN ANTI-ATHEROSCLEROSIS AND RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12582712
Method of Making Anti-Pro/Latent Myostatin Antibodies
2y 5m to grant Granted Mar 24, 2026
Patent 12577300
NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN
2y 5m to grant Granted Mar 17, 2026
Patent 12577301
GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78
2y 5m to grant Granted Mar 17, 2026
Patent 12559545
HUMAN HENDRA VIRUS AND NIPAH VIRUS ANTIBODIES AND METHODS OF USE THEREFOR
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+38.3%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 940 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month